Methanolic extract of white asparagus shoots activates TRAIL apoptotic death pathway in human cancer cells and inhibits colon carcinogenesis in a preclinical model

Bousserouel,Souad; Le Grandois,Julie; Gossé,Francine; Werner,Dalal; Barth,Stephan  W.; Marchioni,Eric; Marescaux,Jacques; Raul,Francis

doi:10.3892/ijo.2013.1976

Methanolic extract of white asparagus shoots activates TRAIL apoptotic death pathway in human cancer cells and inhibits colon carcinogenesis in a preclinical model

Authors:
- Souad Bousserouel
- Julie Le Grandois
- Francine Gossé
- Dalal Werner
- Stephan W. Barth
- Eric Marchioni
- Jacques Marescaux
- Francis Raul
View Affiliations

Affiliations: University of Strasbourg, Unit EA 4438, Faculty of Medicine, Strasbourg, France, AERIAL, Illkirch, France, Max Rubner Institute, Karlsruhe, Germany, University of Strasbourg, Faculty of Pharmacy, IPHC, CNRS-UMR7178, Illkirch, France, Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD), Strasbourg, France
Published online on: June 7, 2013 https://doi.org/10.3892/ijo.2013.1976
Pages: 394-404
Copyright: © Bousserouel et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Shoots of white asparagus are a popular vegetable dish, known to be rich in many bioactive phytochemicals reported to possess antioxidant, and anti-inflammatory and antitumor activities. We evaluated the anticancer mechanisms of a methanolic extract of Asparagus officinalis L. shoots (Asp) on human colon carcinoma cells (SW480) and their derived metastatic cells (SW620), and Asp chemopreventive properties were also assessed in a model of colon carcinogenesis. SW480 and SW620 cell proliferation was inhibited by 80% after exposure to Asp (80 µg/ml). We demonstrated that Asp induced cell death through the activation of TRAIL DR4/DR5 death receptors leading to the activation of caspase-8 and caspase-3 and to cell apoptosis. By specific blocking agents of DR4/DR5 receptors we were able to prevent Asp-triggered cell death confirming the key role of DR4/DR5 receptors. We found also that Asp (80 µg/ml) was able to potentiate the effects of the cytokine TRAIL on cell death even in the TRAIL-resistant metastatic SW620 cells. Colon carcinogenesis was initiated in Wistar rats by intraperitoneal injections of azoxymethane (AOM), once a week for two weeks. One week after (post-initiation) rats received daily Asp (0.01%, 14 mg/kg body weight) in drinking water. After 7 weeks of Asp-treatment the colon of rats exhibited a 50% reduction of the number of preneoplastic lesions (aberrant crypt foci). In addition Asp induced inhibition of several pro-inflammatory mediators, in association with an increased expression of host-defense mediators. In the colonic mucosa of Asp-treated rats we also confirmed the pro-apoptotic effects observed in vitro including the activation of the TRAIL death‑receptor signaling pathway. Taken together, our data highlight the chemopreventive effects of Asp on colon carcinogenesis and its ability to promote normal cellular homeostasis.

View Figures

View References

1.	Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R and Sigman CC: Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev. 3:85–98. 1994.PubMed/NCBI
2.	Kelloff GJ, Boone CW, Crowell JA, Steele VE, Luber RA, Doody LA, Malone WF, Hawk ET and Sigman CC: New agents for cancer chemoprevention. J Cell Biochem (Suppl). 26:1–28. 1996. View Article : Google Scholar
3.	Corpet DE and Taché S: Most effective colon cancer chemo-preventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer. 43:1–21. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Tanaka T and Sugie S: Inhibition of colon carcinogenesis by dietary non-nutritive compounds. J Toxicol Pathol. 20:215–235. 2007. View Article : Google Scholar
5.	Kushi LH, Meyer KA and Jacobs DR Jr: Cereals, legumes, and chronic disease risk reduction: evidence from epidemiologic studies. Am J Clin Nutr. 70:451S–458S. 1999.PubMed/NCBI
6.	Bobe G, Barrett KG, Mentor-Marcel RA, Saffiotti U, Young MR, Colburn NH, Albert PS, Bennink MR and Lanza E: Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced ob/ob mice. Nutr Cancer. 60:373–381. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Steele VE, Pereira MA, Sigman CC and Kelloff GJ: Cancer chemoprevention agent development strategies for genistein. J Nutr. 125:713S–716S. 1995.PubMed/NCBI
8.	Yu S, Poobsasert O, Kennelly EJ, Chin CK, Ho CT, Huang MT, Garrison SA and Cordell GA: Steroidal saponins from Asparagus officinalis and their cytotoxic activity. Planta Medica. 63:258–262. 1997.
9.	Huang X and Kong L: Steroidal saponins from roots of Asparagus officinalis. Steroids. 71:171–176. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Shao Y, Chin CK, Ho CT, Ma W, Garrison SA and Huang MT: Anti-tumor activity of the crude saponins obtained from asparagus. Cancer Lett. 104:31–36. 1996. View Article : Google Scholar : PubMed/NCBI
11.	Wang M, Tadmor Y, Wu QL, Chin CK, Garrison SA and Simon JE: Quantification of protodioscin and rutin in asparagus shoots by LC/MS and HPLC methods. J Agric Food Chem. 51:6132–6136. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Makris DP and Rossiter JT: Domestic processing of onion bulbs (Allium cepa) and asparagus spears (Asparagus officinalis): effect on flavonol content and antioxidant status. J Agric Food Chem. 49:3216–3222. 2001.PubMed/NCBI
13.	Villanueva-Suarez MJ, Redondo-Cuenca A, Rodriguez-Sevilla MD and Heredia-Moreno A: Postharvest storage of white asparagus (Asparagus officinalis I.): changes in dietary fiber (Nonstarch polysaccharides). J Agric Food Chem. 47:3832–3836. 1999.PubMed/NCBI
14.	Yamamori A, Onodera S, Kikuchi M and Shiomi N: Two novel oligosaccharides formed by 1F-fructosyltransferase purified from roots of asparagus (Asparagus officinalis L.). Biosci Biotechnol Biochem. 66:1419–1422. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Rodriguez R, Jaramillo S, Rodriguez G, Espejo JA, Guillén R, Fernandez-Bolanos J, Heredia A and Jiménez A: Antioxidant activity of ethanolic extracts from several asparagus cultivars. J Agric Food Chem. 53:5212–5217. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Jang DS, Cuendet M, Fong HH, Pezzuto JM and Kinghorn AD: Constituents of Asparagus officinalis evaluated for inhibitory activity against cyclooxygenase-2. J Agric Food Chem. 52:2218–2222. 2004.PubMed/NCBI
17.	Mei HS, Wu YQMG and Wu ZY: The effects by eating asparagus spears on blood-lipid levels of human body. Acta Sci Nat Univ Pekin. 26:369–372. 1990.
18.	Wang H and Ng TB: Isolation of a novel deoxyribonuclease with antifungal activity from Asparagus officinalis seeds. Biochem Biophys Res Commun. 289:120–124. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Huang J, Sun Y and Lu S: Experimental study on apoptosis induced by ursolic acid isolated from asparagus in HL-60 cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 19:296–298. 1999.(In Chinese).
20.	Liu W, Huang XF, Qi Q, Dai QS, Yang L, Nie FF, Lu N, Gong DD, Kong LY and Guo QL: Asparanin A induces G(2)/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochem Biophys Res Commun. 381:700–705. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Bhutani KK, Paul AT, Fayad W and Linder S: Apoptosis inducing activity of steroidal constituents from Solanum xanthocarpum and Asparagus racemosus. Phytomedicine. 17:789–793. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW and Stetler-Stevenson WG: Validation of a model of colon cancer progression. J Pathol. 192:446–454. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Reddy BS: Studies with azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen. 44:26–35. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon cancer chemoprevention in rats, mice and humans. Eur J Cancer. 41:1911–1922. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Bousserouel S, Gossé F, Bouhadjar M, Soler L, Marescaux J and Raul F: Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 23:511–517. 2010.
26.	Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis. 15:1049–1054. 1994. View Article : Google Scholar
27.	Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kogawa K, Miyake H and Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
28.	Bird RP and Good CK: The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett. 112–113:395–402. 2000.
29.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
30.	Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 1:1458–1461. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Reed JC: Mechanisms of apoptosis. Am J Pathol. 157:1415–1430. 2000. View Article : Google Scholar
32.	Jin Z, McDonald ER III, Dicker DT and El-Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 279:35829–35839. 2004. View Article : Google Scholar
33.	Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev. 87:1285–1342. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R and Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 15:1126–1131. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Buck I, Morceau F, Grigorakaki C, Dicato M and Diederich M: Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem Pharmacol. 77:1572–1579. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Ramasundara M, Leach ST, Lemberg DA and Day AS: Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol. 24:202–208. 2009. View Article : Google Scholar : PubMed/NCBI
38.	Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol. 17:2941–2953. 1999.PubMed/NCBI
39.	Wang S: TRAIL: a sword for killing tumors. Curr Med Chem. 17:3309–3317. 2010. View Article : Google Scholar : PubMed/NCBI
40.	Bellail AC, Qi L, Mulligan P, Chhabra V and Hao C: TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 4:34–41. 2009. View Article : Google Scholar : PubMed/NCBI
41.	Thorburn A, Behbakht K and Ford H: Trail receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat. 11:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
42.	Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee JH and Kong AN: Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their drug ability. Anticancer Agents Med Chem. 12:1281–1305. 2012. View Article : Google Scholar : PubMed/NCBI
43.	Kong CK, Lam WS, Chiu LC, Ooi VE, Sun SS and Wong YS: A rice bran polyphenol, cycloartenyl ferulate, elicits apoptosis in human colorectal adenocarcinoma SW480 and sensitizes metastatic SW620 cells to TRAIL-induced apoptosis. Biochem Pharmacol. 77:1487–1496. 2009. View Article : Google Scholar
44.	Kauntz H, Bousserouel S, Gossé F and Raul F: The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis. 17:797–809. 2012. View Article : Google Scholar
45.	Lu H, Ouyang W and Huang C: Inflammation, a key event in cancer development. Mol Cancer Res. 4:221–233. 2006. View Article : Google Scholar : PubMed/NCBI
46.	Fingleton B, Vargo-Gogola T, Crawford HC and Matrisian LM: Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 3:459–468. 2001. View Article : Google Scholar : PubMed/NCBI
47.	Nyormoi O, Mills L and Bar-Eli M: An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 10:558–569. 2003. View Article : Google Scholar : PubMed/NCBI
48.	Friedl P and Wolf K: Tumor-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer. 3:362–374. 2003. View Article : Google Scholar : PubMed/NCBI
49.	Johansson N, Ahonen M and Kähäri VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 57:5–15. 2000. View Article : Google Scholar
50.	Rajput ZI, Hu SH, Xiao CW and Arijo AG: Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B. 8:153–161. 2007. View Article : Google Scholar : PubMed/NCBI
51.	Sabater-Molina M, Larqué E, Torrella F and Zamora S: Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem. 65:215–328. 2009. View Article : Google Scholar
52.	Chien MH, Ying TH, Yang SF, Yu JK, Hsu CW, Hsieh SC and Hsieh YH: Lipocalin-2 induces apoptosis in human hepatocellular carcinoma cells through activation of mitochondria pathways. Cell Biochem Biophys. 64:177–186. 2012. View Article : Google Scholar : PubMed/NCBI
53.	Papo N and Shai Y: Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci. 62:784–790. 2005. View Article : Google Scholar : PubMed/NCBI
54.	Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y and Kim JS: Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer. 118:2490–2497. 2006. View Article : Google Scholar
55.	Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV and Radford-Smith GL: Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease. Gut. 57:903–910. 2008.
56.	Friedl A, Stoesz SP, Buckley P and Gould MN: Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 31:433–441. 1999. View Article : Google Scholar : PubMed/NCBI
57.	Shi J, Aono S, Lu W, Ouellette AJ, Hu X, Ji Y, Wang L, Lenz S, van Ginkel FW, Liles M, Dykstra C, Morrison EE and Elson CO: A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol. 179:1245–1253. 2007. View Article : Google Scholar : PubMed/NCBI